Skip to main content
Psychedex

6Node page

what any key link opens

psx:substance/lsd/value/contraindication/050f9ab0-f096-4e44-91f3-3a53d053c1f1@1

valuereferenced by edges — no row of its own

derived from · upstream

feeds · downstream

none recorded

Closure of psx:substance/lsd/value/contraindication/050f9ab0-f096-4e44-91f3-3a53d053c1f1@1: 1 upstream, 0 downstream.

psx:substance/lsd/value/contraindication/050f9ab0-f096-4e44-91f3-3a53d053c1f1@1
└─ derived_from  proposal/contraindication/ff816139-c5f6-42c5-85ad-b7ac79b13b75  contraindication · cardiovascular

indented by distance from this node, not by parentage

1Provenance card

the boundary, as counts

Sources

3331 with DOI

26 strong · 6 moderate · 1 weak

Compilations

0no compilation run

16 other runs

Decisions

75last ruled 2026-10-03

32 awaiting a ruling

Issued documents

102026-10-19T20:32:32.507Z

notice · info card · emergency

Searches

00 with no results

queries and counts on the build

Claims checked

10274 supported

74 supported · 28 not

Correspondence

0received

consent field ships in Phase 4

Edges

341

derivations recorded for this entity

Complete over 33 sources and 75 decisions.Not here: the private journal (never); 32 proposals awaiting a ruling (listed as pending only).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/lsd/archive

2Build

one panel per compilation run

Other runs

  1. findings run2026-08-19failed15 min102 entriesrun/1c0ee90a…
  2. findings run2026-08-19failed15 minrun/9bfe8fae…
  3. findings run2026-08-19failed45 minrun/6b59a6a5…
  4. findings run2026-08-20completed29 minrun/bd5dfd79…
  5. brief run2026-09-18failed15 minrun/17d1cf3a…
  6. brief run2026-09-18failed23 minrun/174d8129…
  7. brief run2026-09-18completed15 minrun/277733d4…
  8. brief run2026-09-22completed4 minrun/3ab2c8cc…
  9. brief run2026-09-22completed5 minrun/cf82bfe4…
  10. brief run2026-09-23completed2 minrun/af0dca76…
  11. brief run2026-09-27completed3 minrun/74090ed1…
  12. brief run2026-09-27completed3 minrun/69f96ff8…
  13. brief run2026-09-27completed6 minrun/9c00cf4b…
  14. brief run2026-09-27completed4 minrun/2805f59c…
  15. brief run2026-09-27completed4 minrun/507aef3b…
  16. brief run2026-09-28completed3 minrun/a03fe9e2…

3Sources

32 consumed · sorted by year · feeds = sections resting on it

Sources 1 to 30
yearsourcetierstatusfeeds
2026LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trialDaldegan-Bueno D, Donegan CJ, Sumner R, Forsyth A, et al., Muthukumaraswamy S · Progress in Neuro-Psychopharmacology and Biological Psychiatrydoi:10.1016/j.pnpbp.2026.111645moderateconsumed1 section
2025Absolute Oral Bioavailability and Bioequivalence of LSD Base and Tartrate in a Double-Blind, Placebo-Controlled, Crossover StudyArikci D, Holze F, Mueller L, Vizeli P, Rudin D, Luethi D, Hysek CM, Liechti ME · Clinical Pharmacology and Therapeuticsdoi:10.1002/cpt.3726strongconsumed2 sections
2025Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre-Administration in a Randomized, Double-Blind, Cross-Over Phase I TrialBecker AM, Humbert-Droz M, Mueller L, Jelušić A, Tolev A, Straumann I, Avedisian I, Erne L, Thomann J, Luethi D, Grünblatt E, Meyer Zu Schwabedissen H, Liechti ME · Clinical Pharmacology and Therapeuticsdoi:10.1002/cpt.3618strongconsumed3 sections
2025Pharmacological Treatment of Hallucinogen Persisting Perception Disorder (HPPD): A Systematic ReviewNeven A, Blom JD · Harvard Review of Psychiatrydoi:10.1097/hrp.0000000000000439strongconsumedcited only
2025Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studiesSabé M, Sulstarova A, Glangetas A, De Pieri M, et al., Kirschner M · Molecular Psychiatrydoi:10.1038/s41380-024-02800-5strongconsumed1 section
2024Chemistry/structural biology of psychedelic drugs and their receptor(s)Gumpper RH, Nichols DE · British Journal of Pharmacologydoi:10.1111/bph.17361strongconsumed2 sections
2024LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-upHolze F, Gasser P, Müller F, Strebel M, Liechti ME · British Journal of Psychiatrydoi:10.1192/bjp.2024.99moderateconsumed1 section
2024Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxinsRouaud A, Calder AE, Hasler G · Journal of Psychopharmacologydoi:10.1177/02698811231225609strongconsumed1 section
2024New-Onset Seizures in an Adolescent Following Use of LSD while on Low-Dose Lithium Therapy: A Case StudyEdwards C, Van Gerpen S, Anand V · South Dakota Medicinepmid:38986146moderateconsumed1 section
2024Pharmacological and non-pharmacological predictors of the LSD experience in healthy participantsVizeli P, Studerus E, Holze F, Schmid Y, Dolder PC, Ley L, Straumann I, Becker AM, Müller F, Arikci D, Liechti ME · Translational Psychiatrydoi:10.1038/s41398-024-03074-9strongconsumed1 section
2023Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participantsLey L, Holze F, Arikci D, Becker AM, Straumann I, Klaiber A, Coviello F, Dierbach S, Thomann J, Duthaler U, Luethi D, Varghese N, Eckert A, Liechti ME · Neuropsychopharmacologydoi:10.1038/s41386-023-01607-2strongconsumed5 sections
2023Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II StudyHolze F, Gasser P, Müller F, Dolder PC, Liechti ME · Biological Psychiatrydoi:10.1016/j.biopsych.2022.08.025strongconsumed1 section
2023Psychedelics promote plasticity by directly binding to BDNF receptor TrkBMoliner R, Girych M, Brunello CA, Kovaleva V, Biojone C, Enkavi G, Antenucci L, Kot EF, Goncharuk SA, Kaurinkoski K, Kuutti M, Fred SM, Elsilä LV, Sakson S, Cannarozzo C, Diniz CRAF, Seiffert N, Rubiolo A, Haapaniemi H, Meshi E, Nagaeva E, Öhman T, Róg T, Kankuri E, Vilar M, Varjosalo M, Korpi ER, Permi P, Mineev KS, Saarma M, Vattulainen I, Casarotto PC, Castrén E · Nature Neurosciencedoi:10.1038/s41593-023-01316-5strongconsumed3 sections
2022Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjectsHolze F, Ley L, Müller F, Becker AM, Straumann I, Vizeli P, Kuehne SS, Roder MA, Duthaler U, Kolaczynska KE, Varghese N, Eckert A, Liechti ME · Neuropsychopharmacologydoi:10.1038/s41386-022-01297-2strongconsumed2 sections
2022Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participantsMüller F, Kraus E, Holze F, Becker A, Ley L, Schmid Y, Vizeli P, Liechti ME, Borgwardt S · Psychopharmacologydoi:10.1007/s00213-022-06066-zstrongconsumed1 section
2022Safety pharmacology of acute LSD administration in healthy subjectsHolze F, Caluori TV, Vizeli P, Liechti ME · Psychopharmacologydoi:10.1007/s00213-021-05978-6strongconsumed1 section
2021A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteersRamaekers JG, Hutten N, Mason NL, Dolder P, Theunissen EL, Holze F, Liechti ME, Feilding A, Kuypers KP · Journal of Psychopharmacologydoi:10.1177/0269881120940937strongconsumedcited only
2021Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjectsHolze F, Vizeli P, Müller F, Ley L, Duerig R, Varghese N, Zizzari P, Liechti ME · Neuropsychopharmacologydoi:10.1038/s41386-020-00883-6strongconsumed3 sections
2021Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reportsJohnson MW, et al.url:2d4d277ba0208a82weakconsumedcited only
2021Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysisVizeli P, Straumann I, Holze F, Schmid Y, Dolder PC, Liechti ME · Scientific Reportsdoi:10.1038/s41598-021-90343-ystrongconsumed2 sections
2021Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy ParticipantsHolze F, Liechti ME, Hutten NRPW, Mason NL, Dolder PC, Theunissen EL, Duthaler U, Feilding A, Ramaekers JG, Kuypers KPC · Clinical Pharmacology and Therapeuticsdoi:10.1002/cpt.2057strongconsumed2 sections
2020Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin ReceptorKim K, Che T, Panova O, DiBerto JF, Lyu J, Krumm BE, Wacker D, Robertson MJ, Seven AB, Nichols DE, Shoichet BK, Skiniotis G, Roth BL · Celldoi:10.1016/j.cell.2020.08.024strongconsumed3 sections
2018A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPDHalpern JH, Lerner AG, Passie T · Current Topics in Behavioral Neurosciencesdoi:10.1007/7854_2016_457moderateconsumed1 section
2018Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic PerspectivesMartinotti G, Santacroce R, Pettorruso M, Montemitro C, Spano MC, Lorusso M, Di Giannantonio M, Gallimberti L · Brain Sciencesdoi:10.3390/brainsci8030047moderateconsumed1 section
2018Psychedelics Promote Structural and Functional Neural PlasticityLy C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, Burbach KF, Soltanzadeh Zarandi S, Sood A, Paddy MR, Duim WC, Dennis MY, McAllister AK, Ori-McKenney KM, Gray JA, Olson DE · Cell Reportsdoi:10.1016/j.celrep.2018.05.022strongconsumed2 sections
2017Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy SubjectsDolder PC, Schmid Y, Steuer AE, Kraemer T, Rentsch KM, Hammann F, Liechti ME · Clinical Pharmacokineticsdoi:10.1007/s40262-017-0513-9strongconsumed2 sections
2016Increased Global Functional Connectivity Correlates with LSD-Induced Ego DissolutionTagliazucchi E, Roseman L, Kaelen M, Orban C, Muthukumaraswamy SD, Murphy K, Laufs H, Leech R, McGonigle J, Crossley N, Bullmore E, Williams T, Bolstridge M, Feilding A, Nutt DJ, Carhart-Harris R · Current Biologydoi:10.1016/j.cub.2016.02.010strongconsumed2 sections
2016Neural correlates of the LSD experience revealed by multimodal neuroimagingCarhart-Harris RL, Muthukumaraswamy S, Roseman L, Kaelen M, Droog W, Murphy K, Tagliazucchi E, Schenberg EE, Nest T, Orban C, Leech R, Williams LT, Williams TM, Bolstridge M, Sessa B, McGonigle J, Sereno MI, Nichols D, Hellyer PJ, Hobden P, Evans J, Singh KD, Wise RG, Curran HV, Feilding A, Nutt DJ · Proceedings of the National Academy of Sciencesdoi:10.1073/pnas.1518377113strongconsumed1 section
2016PsychedelicsNichols DE · Pharmacological Reviewsdoi:10.1124/pr.115.011478strongconsumed7 sections
2015Acute Effects of Lysergic Acid Diethylamide in Healthy SubjectsSchmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, Brenneisen R, Müller F, Borgwardt S, Liechti ME · Biological Psychiatrydoi:10.1016/j.biopsych.2014.11.015strongconsumed2 sections
Show all 33 sources — 3 more
Sources 31 to 33
yearsourcetierstatusfeeds
2014The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugsCarhart-Harris RL, Leech R, Hellyer PJ, Shanahan M, Feilding A, Tagliazucchi E, Chialvo DR, Nutt D · Frontiers in Human Neurosciencedoi:10.3389/fnhum.2014.00020strongconsumed1 section
2012Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trialsKrebs TS, Johansen PØ · Journal of Psychopharmacologydoi:10.1177/0269881112439253strongconsumedcited only
—Crystal Structure of an LSD-Bound Human Serotonin Receptordoi:10.1016/j.cell.2016.12.033—unknowncited only

4Docket

one filing per activity — decisions, correspondence, reports

awaiting ruling — 32

  • safety_finding · oral · toxicity · safety_margincited2026-08-20
  • safety_finding · toxicity · mortality_record2026-08-20
  • safety_finding · toxicity · adulterant_hazard2026-08-20
  • safety_finding · toxicity · acute_toxicitycited2026-08-20
  • safety_finding · toxicity · cardiovascularcited2026-08-20
  • safety_finding · toxicity · cardiovascularcited2026-08-20
  • safety_finding · toxicity · receptor_concern2026-08-20
  • safety_finding · toxicity · cardiovascular2026-08-20
  • safety_finding · toxicity · study_safetycited2026-08-20
  • safety_finding · toxicity · study_safetycited2026-08-20
  • safety_finding · psychological_risks · hppd2026-08-20
  • safety_finding · psychological_risks · hppd2026-08-20
  • safety_finding · psychological_risks · hppd2026-08-20
  • safety_finding · psychological_risks · hppdcited2026-08-20
  • safety_finding · psychological_risks · hppd2026-08-20
  • safety_finding · psychological_risks · psychosiscited2026-08-20
  • safety_finding · psychological_risks · psychosiscited2026-08-20
  • safety_finding · psychological_risks · psychosis2026-08-20
  • safety_finding · toxicity · serotonergic2026-08-20
  • safety_finding · toxicity · serotonergic2026-08-20
  • safety_finding · toxicity · neurological2026-08-20
  • safety_finding · toxicity · neurologicalcited2026-08-20
  • safety_finding · toxicity · neurologicalcited2026-08-20
  • safety_finding · toxicity · neurologicalcited2026-08-20
  • safety_finding · toxicity · serotonergic2026-08-20
  • safety_finding · oral · toxicity · serotonergiccited2026-08-20
  • safety_finding · oral · toxicity · study_safetycited2026-08-20
  • safety_finding · toxicity · serotonergic2026-08-20
  • safety_finding · toxicity · serotonergic2026-08-20
  • safety_finding · toxicity · reproductive2026-08-20
  • safety_finding · toxicity · neurological2026-08-20
  • safety_finding · toxicity · cardiovascular2026-08-20
  1. 0012026-04-19revisionRevision 1

    Initial LLM generation (v5 pipeline, wiki)

    psx:substance/lsd/version/1
  2. 0022026-06-04proposal30 value proposals approved together

    one review action inferred from a shared reviewer and instant — the graph records one activity per proposal

    30 items in this filing

    • dose_tier · light
    • dose_tier · common
    • dose_tier · strong
    • dose_tier · heavy
    • timeline · oral · onset
    • timeline · oral · come_up
    • timeline · oral · ascent
    • timeline · oral · peak
    • timeline · oral · plateau
    • timeline · oral · resolution
    • timeline · oral · afterglow
    • toxicity
    • dependence · full
    • withdrawal
    • tolerance
    • dosage · oral
    • duration · oral · onset
    • duration · oral · come_up
    • duration · oral · peak
    • duration · oral · offset
    • duration · oral · total
    • duration · oral · aftereffects
    • contraindication · psychiatric
    • contraindication · psychiatric
    • contraindication · neurological
    • contraindication · other
    • contraindication · cardiovascular
    • contraindication · pregnancy_breastfeeding
    • contraindication · other
    psx:substance/lsd/proposal/dose_tier/d6efb877-0f42-4a97-9d6f-87b5494be767
  3. 0032026-06-04publicationPublication — backfill
    psx:substance/lsd/pub/00599d13-ba7d-4297-9b8f-891432285be2
  4. 0042026-08-24revisionr1.a1

    technical error

    psx:substance/lsd/version/2
  5. 0052026-09-20revisionr1.a2

    no edit summary recorded

    psx:substance/lsd/version/3
  6. 0062026-09-20publicationPublication — publishagent-psx (local dev)
    psx:substance/lsd/pub/0a6947c9-2333-4664-a19f-57c014faae3c
  7. 0072026-09-22revisionr1.a3

    no edit summary recorded

    psx:substance/lsd/version/4
  8. 0082026-09-23publicationPublication — publishChris
    psx:substance/lsd/pub/422f95e7-5178-45dc-b74d-d27166557943
  9. 0092026-09-23revisionr1.a4

    no edit summary recorded

    psx:substance/lsd/version/5
  10. 0102026-09-24publicationPublication — publishagent-psx (local dev)
    psx:substance/lsd/pub/ac271cc8-474f-4a8f-aabc-da71153b8db7
  11. 0112026-09-27revisionr1.a5

    brief-overview retired 2026-09-30 (founder): Description reads the essential summary for every substance.

    psx:substance/lsd/version/6
  12. 0122026-10-03revisionr1.a6

    Restore reagent testing, appearance and the identification guide carried by r1. They were dropped when amendment r1.a2 was created on 2026-09-20: the amendment copier carried only the summary columns (fixed 7d6e6ade8). Values copied unchanged from r1.

    psx:substance/lsd/version/7
  13. 0132026-10-03publicationPublication — publishagent-psx
    psx:substance/lsd/pub/129688e3-a57d-44b1-9968-d7197c942c5e
  14. 0142026-10-03revisionr1.a7

    no edit summary recorded

    psx:substance/lsd/version/8

5Issued documents

what the notice, info card and emergency page said, by hash

Issued documents
documentcontent hashissuedfrom versionsuperseded
emergencyc15c760aabf6f0fcf5b6fc6b…2026-10-19 20:32Revision 7current
info_carda8d971188c3ca510a5c975fe…2026-10-19 20:32Revision 7current
info_card4c6647f545c338ee3cbb4a63…2026-10-03 21:31Revision 7superseded2026-10-19
info_card5663c86ee3b8f14c6bfbe8f8…2026-09-24 10:06Revision 5superseded2026-10-03
info_card2a2db6475e85b8efd25000be…2026-09-23 07:47Revision 4superseded2026-09-24
noticef069a9dea47b308467344618…2026-09-23 07:47Revision 4current
info_cardab88b29eebc8cacc6ecfe7af…2026-09-20 08:15Revision 3superseded2026-09-23
emergency3f0909c25c714d225b4bb3e3…2026-09-04 04:30Revision 1superseded2026-10-19
info_card661b6d0eb350b1e2bb2cc63c…2026-09-04 04:30Revision 1superseded2026-09-20
notice64878b43a1d2932a5305f55b…2026-09-04 04:30Revision 1superseded2026-09-23